In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 351 to 374 of 374

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance	TBC
Unilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor	HealthTech guidance	17 December 2026
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance	14 October 2026
Vamikibart for treating uveitic macular oedema ID6671	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance	TBC
Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)	NICE guideline	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]	Technology appraisal guidance	TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]	Technology appraisal guidance	22 November 2017
Women's and reproductive health guidelines	NICE guideline	TBC
Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716	Technology appraisal guidance	TBC
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672	Technology appraisal guidance	TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	3 September 2026
Zio XT for detecting cardiac arrhythmias	Medical technologies guidance	TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]	Technology appraisal guidance	TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573	Technology appraisal guidance	TBC
Zuranolone for treating postnatal depression [ID6431]	Technology appraisal guidance	TBC

Results per page

10
25
50
All